Skip to main content

Table 1 Statistics of BC patients in New Hampshire 2010–2016

From: Patient and physician factors associated with Oncotype DX and adjuvant chemotherapy utilization for breast cancer patients in New Hampshire, 2010–2016

Variable

ODX Not Given (n = 4118)

ODX Given (n = 1512)

Total (n = 5630)

P-Value

Patient Age at Diagnosis (Years)

< 0.01**

 < 50

7870 (18.9%)

317 (21.0%)

1097 (19.5%)

 

 50–59

974 (23.7%)

447 (29.6%)

1421 (25.2%)

 

 60–69

1166 (28.3%)

518 (34.3%)

1684 (29.9%)

 

 > 69

1198 (29.1%)

230 (15.2%)

1428 (25.4%)

 

Marital Status

< 0.01**

 Single

1620 (39.3%)

464 (30.7%)

2084 (37.0%)

 

 Married

2391 (58.1%)

1010 (66.8%)

3401 (60.4%)

 

 Unknown

107 (2.6%)

38 (2.5%)

145 (2.6%)

 

Payer

< 0.01**

 Self-Pay

86 (2.1%)

18 (1.2%)

104 (1.8%)

 

 Public

1901 (46.2%)

516 (34.1%)

2417 (42.9%)

 

 Private

1659 (40.3%)

790 (52.2%)

2449 (43.5%)

 

 Unknown

472 (11.5%)

188 (12.4%)

660 (11.7%)

 

Year of Diagnosis

0.14

 2010

526 (12.8%)

172 (11.4%)

698 (12.4%)

 

 2011

577 (14.0%)

198 (13.1%)

775 (13.8%)

 

 2012

528 (12.8%)

185 (12.2%)

713 (12.7%)

 

 2013

580 (14.1%)

189 (12.5%)

769 (13.7%)

 

 2014

613 (14.9%)

242 (16.0%)

855 (15.2%)

 

 2015

668 (16.2%)

269 (17.8%)

937 (16.6%)

 

 2016

626 (15.2%)

257 (17.0%)

883 (15.7%)

 

Tumor Size (mm)

< 0.01**

 0.1–19

2390 (58.0%)

1023 (67.7%)

3413 (60.6%)

 

 20–39

981 (23.8%)

417 (27.6%)

1398 (24.8%)

 

 > 40

627 (15.2%)

64 (4.2%)

691 (12.3%)

 

 Unknown

120 (2.9%)

8 (0.5%)

128 (2.3%)

 

Tumor Grade

< 0.01**

 I

854 (20.7%)

398 (26.3%)

1252 (22.2%)

 

 II

1719 (41.7%)

844 (55.8%)

2563 (45.5%)

 

 III / IV

1403 (34.1%)

265 (17.5%)

1668 (29.6%)

 

 Unknown

142 (3.4%)

5 (0.3%)

147 (2.6%)

 

LN Status

< 0.01**

 Negative

2289 (55.6%)

1196 (79.1%)

3485 (61.9%)

 

 Positive

1257 (30.5%)

284 (18.8%)

1541 (27.4%)

 

 Unknown

572 (13.9%)

32 (2.1%)

604 (10.7%)

 

ER/PR/HER2 Status

< 0.01**

 HR+/HER2-

2663 (64.7%)

1446 (95.6%)

4109 (73.0%)

 

 Other

1270 (30.8%)

41 (2.7%)

1311 (23.3%)

 

 Unknown

185 (4.5%)

25 (2.5%)

210 (3.7%)

 

Clinical Stage

< 0.01**

 1

2152 (52.3%)

1034 (68.4%)

3186 (56.6%)

 

 2

1166 (28.3%)

453 (30.0%)

1619 (28.8%)

 

 3 / 4

800 (19.4%)

25 (1.7%)

825 (14.7%)

 

ODX Eligiblea

1472 (35.7%)

1132 (74.9%)

2604 (46.3%)

< 0.01**

MD Gender

0.34

 Female

2212 (53.7%)

790 (52.2%)

3002 (53.3%)

 

 Male

1906 (46.3%)

722 (47.8%)

2628 (46.7%)

 

MD Clinical Experience (Years)

0.08

 < 10

169 (4.1%)

58 (3.8%)

227 (4.0%)

 

 10–19

1774 (43.1%)

604 (39.9%)

2378 (42.2%)

 

 20–29

1254 (30.5%)

511 (33.8%)

1765 (31.3%)

 

 > 29

921 (22.4%)

339 (22.4%)

1260 (22.4%)

 

Surgical Specialty

0.72

 General Surgeon

3582 (87.0%)

1309 (86.6%)

4891 (86.9%)

 

 Surgical Oncologist

536 (13.0%)

203 (13.4%)

739 (13.1%)

 
  1. P-values were calculated using chi-square test for categorical variables
  2. * significant at the 0.05 level
  3. ** significant at the 0.01 level
  4. aODX eligible patients are defined as stage 1 or 2, LN negative, and HR+/HER2-